ArQule Presents Additional Clinical Biomarker Data From Phase 2 Study of Tivantinib in Hepatocellular Carcinoma at International Liver Cancer Association Conference
08 sept. 2015 07h30 HE
|
ArQule, Inc.
BURLINGTON, Mass., Sept. 08, 2015 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced that additional analyses of plasma biomarkers support the prognostic and predictive role of MET...
ArQule Reports Second Quarter 2015 Financial Results
05 août 2015 07h00 HE
|
ArQule, Inc.
BURLINGTON, Mass., Aug. 05, 2015 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced its financial results for the second quarter of 2015. For the quarter ended June 30, 2015,...